Key Takeaways From ASCRS 2025: Understanding Recent Data for Treating Dry Eye Disease
A panelist discusses how recent clinical studies on dry eye disease emphasize the importance of precise diagnosis and targeted treatments such as cyclosporine formulations and varenicline nasal spray in improving tear film stability, reducing inflammation, and enhancing patient outcomes, while highlighting challenges such as delayed symptom relief, medication adherence, and the need for ongoing research into meibomian gland dysfunction.
Episodes
June 13th 2025EP. 1: Dry Eye Disease: Pathophysiology, Impact, and Standard of Care
A panelist discusses how dry eye disease involves tear film imbalance, leading to inflammation and ocular surface damage, emphasizing the importance of precise diagnosis and tailored treatment while acknowledging ongoing challenges with patient expectations, medication access, delayed symptom relief, and treatment adherence.
June 20th 2025EP. 2: The COAT Trial: Evaluating Ocular Surface Health in DED
A panelist discusses how the COAT trial demonstrated that twice-daily 0.09% cyclosporine improves multiple signs and symptoms of dry eye disease within 28 days, highlighting the value of early monitoring to optimize patient adherence and treatment outcomes.
June 27th 2025EP. 3: Crossover Study: Nanomicellar Cyclosporine 0.09% vs Emulsion Cyclosporine 0.05%
A panelist discusses how the COAT trial showed that switching patients with uncontrolled dry eye disease on cyclosporine 0.05% to the 0.09% solution led to significant improvements in corneal staining and symptoms by week 4, offering earlier relief than typically expected and supporting informed patient counseling.
